Results 21 to 30 of about 34,307 (290)

HIV Entry and Its Inhibition by Bifunctional Antiviral Proteins

Molecular Therapy: Nucleic Acids, 2018
HIV entry is a highly specific and time-sensitive process that can be divided into receptor binding, coreceptor binding, and membrane fusion. Bifunctional antiviral proteins (bAVPs) exploit the multi-step nature of the HIV entry process by binding to two
Alexander Falkenhagen, Sadhna Joshi
doaj   +1 more source

A compensatory mutation provides resistance to disparate HIV fusion inhibitor peptides and enhances membrane fusion. [PDF]

PLoS ONE, 2013
Fusion inhibitors are a class of antiretroviral drugs used to prevent entry of HIV into host cells. Many of the fusion inhibitors being developed, including the drug enfuvirtide, are peptides designed to competitively inhibit the viral fusion protein ...
Matthew P Wood, Amy L Cole, Piotr Ruchala, Alan J Waring, Lisa C Rohan, Preston Marx, Patrick M Tarwater, Phalguni Gupta, Alexander M Cole   +8 more
doaj   +1 more source

A bivalent recombinant protein inactivates HIV-1 by targeting the gp41 prehairpin fusion intermediate induced by CD4 D1D2 domains

Retrovirology, 2012
Background Most currently approved anti-HIV drugs (e.g., reverse transcriptase inhibitors, protease inhibitors and fusion/entry inhibitors) must act inside or on surface of the target cell to inhibit HIV infection, but none can directly inactivate ...
Lu Lu, Pan Chungen, Li Yuan, Lu Hong, He Wu, Jiang Shibo   +5 more
doaj   +1 more source

An inducible cell-cell fusion system with integrated ability to measure the efficiency and specificity of HIV-1 entry inhibitors. [PDF]

PLoS ONE, 2011
HIV-1 envelope glycoproteins (Envs) mediate virus entry by fusing the viral and target cell membranes, a multi-step process that represents an attractive target for inhibition.
Alon Herschhorn, Andres Finzi, David M Jones, Joel R Courter, Akihiro Sugawara, Amos B Smith, Joseph G Sodroski   +6 more
doaj   +1 more source

Identification of novel neutralizing determinants for protection against HCV

Hepatology, EarlyView., 2022
Identification of novel neutralizing determinants for protection against hepatitis C virus. Abstract Background and Aims HCV evasion of neutralizing antibodies (nAb) results in viral persistence and poses challenges to the development of an urgently needed vaccine.
Garazi P. Alzua, Anne F. Pihl, Anna Offersgaard, Rodrigo Velázquez‐Moctezuma, Carlos R. Duarte Hernandez, Elias H. Augestad, Ulrik Fahnøe, Christian K. Mathiesen, Henrik Krarup, Mansun Law, Jannick Prentoe, Jens Bukh, Judith M. Gottwein   +12 more
wiley   +1 more source

Evidence Showing that Tetraspanins Inhibit HIV-1-Induced Cell-Cell Fusion at a Post-Hemifusion Stage

Viruses, 2014
Human immunodeficiency virus type 1 (HIV-1) transmission takes place primarily through cell-cell contacts known as virological synapses. Formation of these transient adhesions between infected and uninfected cells can lead to transmission of viral ...
Menelaos Symeonides, Marie Lambelé, Nathan H. Roy, Markus Thali   +3 more
doaj   +1 more source

Electron tomography visualization of HIV-1 fusion with target cells using fusion inhibitors to trap the pre-hairpin intermediate

eLife, 2020
Fusion of HIV-1 with the membrane of its target cell, an obligate first step in virus infectivity, is mediated by binding of the viral envelope (Env) spike protein to its receptors, CD4 and CCR5/CXCR4, on the cell surface.
Mark S Ladinsky, Priyanthi NP Gnanapragasam, Zhi Yang, Anthony P West, Michael S Kay, Pamela J Bjorkman   +5 more
doaj   +1 more source

HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay. [PDF]

PLoS ONE, 2018
Human Immunodeficiency Virus-1 (HIV-1) entry is dependent on the envelope glycoprotein (Env) that is present on the virion and facilitates fusion between the envelope and the cellular membrane.
Edward Yang, Matthew R Gardner, Amber S Zhou, Michael Farzan, Ann M Arvin, Stefan L Oliver   +5 more
doaj   +1 more source

The role of the HIV-1 protease substrate in therapy resistance [PDF]

, 2015
In Switzerland and Germany up to a half of the first-line regimens include protease inhibitors (PIs) [1, 2]. Although in the Swiss HIV Cohort Study (SHCS) most patients under antiretroviral therapy (ART) have suppressed viral loads [3], every third ...
Kletenkov, Konstantin
core   +1 more source

Conserved Residue Asn-145 in the C-Terminal Heptad Repeat Region of HIV-1 gp41 is Critical for Viral Fusion and Regulates the Antiviral Activity of Fusion Inhibitors

Viruses, 2019
Entry of HIV-1 into target cells is mediated by its envelope (Env) glycoprotein composed of the receptor binding subunit gp120 and the fusion protein gp41. Refolding of the gp41 N- and C-terminal heptad repeats (NHR and CHR) into a six-helix bundle (6-HB)
Xiuzhu Geng, Zixuan Liu, Danwei Yu, Bo Qin, Yuanmei Zhu, Sheng Cui, Huihui Chong, Yuxian He   +7 more
doaj   +1 more source